Among these, pembrolizumab is a humanized immunoglobulin G4 (IgG4) monoclonal anti-PD-1 antibody that has undergone phase II trials in patients with metastatic or recurrent regional MCC [44]. This evidence concerns the gene PDCD1 and Merkel cell skin cancer.